Form 4: Collegium Pharmaceutical CEO Vikram Karnani Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Collegium Pharmaceutical's CEO, Vikram Karnani, was granted stock options and restricted stock units as part of his compensation.
Summary
- Vikram Karnani, the President and CEO of Collegium Pharmaceutical, received 105,972 restricted stock units (RSUs) and stock options for 130,344 shares on November 12, 2024.
- The RSUs vest 25% on November 12, 2025, with the remaining balance vesting in three annual installments.
- The stock options vest 25% on November 12, 2025, with the remaining balance vesting in equal quarterly installments.
- Both the RSUs and stock options are subject to Karnani's continued service with the company.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative sentiment.
Positives
- The grant of RSUs and stock options aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Risks
- The value of the RSUs and stock options is dependent on the future performance of Collegium's stock price.
- If the CEO leaves the company before the vesting dates, he may forfeit some or all of the unvested RSUs and options.
Future Outlook
The vesting of the RSUs and stock options is contingent on the CEO's continued service with the company, suggesting a focus on long-term performance and stability.
Industry Context
The granting of stock options and restricted stock units is a common practice in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option and RSU grants are standard practice for executive compensation in the pharmaceutical industry, similar to companies like Teva Pharmaceuticals and Mylan.
- The vesting schedules are also typical, with a mix of time-based vesting to encourage long-term commitment, similar to what is seen at companies like Pfizer and AbbVie.
Stakeholder Impact
- Shareholders may view the grant of stock options and RSUs positively as it aligns the CEO's interests with the company's long-term success.
- Employees may see this as a sign of stability and commitment from the company's leadership.
Key Dates
| Date | Description |
|---|---|
| 11/12/2024 | Date of the grant of restricted stock units and stock options. |
| 11/12/2025 | First vesting date for 25% of the restricted stock units and stock options. |
| 11/12/2034 | Expiration date of the stock options. |
| 11/14/2024 | Date the form was signed. |
Keywords
stock options, restricted stock units, RSUs, executive compensation, insider trading, Collegium Pharmaceutical, Vikram Karnani
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.